TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025

Reuters

Jul 24

TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025

TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553789613"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553789613\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553789613?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553789613","market":"fut","top_or_hot":-1,"title":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDL2Qlcly:1","article_id":"2553789613","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553789613","pubTimestamp":1753368488,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025. TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology  Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02410":"同源康医药-B","BK1161":"生物科技"},"translate_title":"TYK Medicines Inc.宣布TY-302、TY-2699a和TY-0540的I期临床试验结果被接受在2025年ESMO大会上展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":0.9},"content_text":"TYK Medicines Inc. Announces Phase I Clinical Trial Results for TY-302, TY-2699a, and TY-0540 Accepted for Presentation at ESMO Congress 2025\n    \n\n        TYK Medicines Inc. has announced that the Phase I clinical trial results for its internally-developed products, TY-302, TY-2699a, and TY-0540, have been accepted for poster presentation at the upcoming 2025 European Society for Medical Oncology (ESMO) Congress. The ESMO Congress, a leading international event in the field of oncology, will take place from October 17 to 21 in Berlin, Germany. The company will present detailed data from these trials during the conference, which involves studies on various cancers, including breast and ovarian cancer. Acceptance for presentation at this prestigious event signifies notable international academic recognition of TYK Medicines' research and development efforts. The company has advised shareholders and potential investors to exercise caution when dealing with its shares, as there is no guaranteed successful development or commercialization of these products.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}